liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trial
Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden.
Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden.
Karolinska Inst, Sweden; Stockholm Cty Council, Sweden.
Lund Univ, Sweden; Malmö Addict Ctr, Sweden.
Show others and affiliations
2025 (English)In: The Lancet Regional Health: Europe, E-ISSN 2666-7762, Vol. 54, article id 101310Article in journal (Refereed) Published
Abstract [en]

Background Alcohol use disorder (AUD) is associated with an enormous burden of disease and cost to society. The dopamine deficiency hypothesis posits that negative reinforcement generated by a low brain dopamine state drives ethanol intake. Here, we evaluated the efficacy and safety of combined administration of two dopamine-enhancing drugs, varenicline (a partial nicotinic acetylcholine receptor agonist) and bupropion (a weak dopamine-reuptake inhibitor) on alcohol intake in AUD. Methods Participants aged 25-70 years with moderate-to-severe AUD (defined as >= 4/11 Diagnostic and Statistical Manual of Mental Disorders [DSM]-5 criteria) were enrolled in this randomized, double-blind, placebo-controlled trial, done at four outpatient clinics in Sweden. Participants were randomly assigned (block size 8) 1:1:1:1 to Placebo + Placebo, Varenicline + Bupropion, Varenicline + Placebo, or Placebo + Bupropion. After a 1-week titration period, Varenicline was taken as 1 mg orally twice per day and bupropion as 150 mg orally twice per day for 12 weeks. Participants, investigators, and all study personnel were unaware of treatment allocation. The two primary outcomes were phosphatidylethanol in blood (B-PEth) and self-reported percentage heavy drinking days (%HDD), assessed over a steady state 10-week-period (from start of week 2 to end of week 11). Modified intention-to-treat (mITT) and per protocol analyses (PP) were performed using a sequential hierarchical statistical method. This registered study (EudraCT 2018-000048-24; clinicaltrials.govNCT04167306) is completed. Findings Between March 4, 2019, and December 14, 2022, 384 participants were randomly assigned: Placebo + Placebo = 97, Varenicline + Bupropion = 100, Varenicline + Placebo = 96, Placebo + Bupropion = 91. 72% participants were male (277/384) and 28% female (107/384), median age 57 (13) years. In the mITT analyses, Varenicline + Bupropion reduced B-PEth (Cohen's d [d] = 0<middle dot>39, p = 0<middle dot>004) and %HDD (d = 0<middle dot>31, p = 0<middle dot>008) vs Placebo + Placebo. Varenicline + Placebo also reduced B-PEth (d = 0<middle dot>30, p = 0<middle dot>005) and %HDD (d = 0<middle dot>36, p = 0<middle dot>023) vs Placebo + Placebo. For both primary endpoints, differences between the Varenicline + Bupropion and Varenicline + Placebo groups were not statistically significant (B-PEth: d = 0<middle dot>022, p = 0<middle dot>97, %HDD: d = 0<middle dot>027, p = 0<middle dot>76), precluding further comparisons according to the statistical hierarchy. In PP analyses, both primary outcomes were reduced with Varenicline + Bupropion (d = 0<middle dot>43 [B-PEth]; d = 0<middle dot>41 [%HDD]) and Varenicline + Placebo (d = 0<middle dot>29 [B-PEth]; d = 0<middle dot>34 [%HDD]) compared with Placebo + Placebo. Nausea, the only safety concern, was more common in the Varenicline + Placebo group than in the Placebo + Placebo group (49/96 vs 11/97, p < 0<middle dot>0001) and of longer median duration (45 (70) vs 10 (14<middle dot>5) days, p = 0<middle dot>001). Nausea incidence was lower in the Varenicline + Bupropion group vs Varenicline + Placebo (36/100 vs 49/96, p = 0<middle dot>048) and of shorter median duration (16<middle dot>5 (39<middle dot>3) vs 45 (70) days, p = 0<middle dot>010). Interpretation Two brain dopamine elevating treatments (Varenicline + Bupropion; Varenicline + Placebo) reduce alcohol consumption compared with placebo alone. Effect sizes were largest when Varenicline and Bupropion were combined and compliance was high (PP-population). Bupropion reduced Varenicline-induced nausea. Varenicline + Bupropion or other mild dopamine enhancers should be further explored for treatment of AUD.

Place, publisher, year, edition, pages
ELSEVIER , 2025. Vol. 54, article id 101310
Keywords [en]
AUD; Bupropion; Combination treatment; RCT; Varenicline
National Category
Drug Abuse and Addiction
Identifiers
URN: urn:nbn:se:liu:diva-214185DOI: 10.1016/j.lanepe.2025.101310ISI: 001492819400002Scopus ID: 2-s2.0-105004945575OAI: oai:DiVA.org:liu-214185DiVA, id: diva2:1962955
Note

Funding Agencies|Swedish Research Council

Available from: 2025-06-02 Created: 2025-06-02 Last updated: 2025-09-12

Open Access in DiVA

fulltext(1631 kB)45 downloads
File information
File name FULLTEXT01.pdfFile size 1631 kBChecksum SHA-512
b2535e844c4df19e5543f084fec4dae2f7b3695ffb82edc611cd6560dc2cb890e0e597c0b209633544d3e49b367e170bc37f369230d97cfb910549b8af5feffa
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Heilig, Markus
By organisation
Center for Social and Affective NeuroscienceFaculty of Medicine and Health SciencesPsykiatriska kliniken i Linköping
In the same journal
The Lancet Regional Health: Europe
Drug Abuse and Addiction

Search outside of DiVA

GoogleGoogle Scholar
Total: 45 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 66 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf